{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:48:34Z","timestamp":1786661314346,"version":"build-2736575974"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":204,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100971","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T23:29:17Z","timestamp":1753399757000},"page":"100971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapy gone viral: Exploring the use of oncolytic viruses in non-small cell lung cancer immunotherapy"],"prefix":"10.1016","volume":"44","author":[{"given":"Jemima","family":"Steele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"Khuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2660-6744","authenticated-orcid":false,"given":"Annwyne","family":"Houldsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100971_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2025.100971_bib0002","first-page":"e1739","article-title":"Effectiveness of immunological agents in non-small cell lung cancer","volume":"6","author":"Rekulapelli","year":"2023","journal-title":"Cancer Rep. (Hob.)"},{"key":"10.1016\/j.ctarc.2025.100971_bib0003","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.100971_bib0004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/0973-1482.187287","article-title":"A prospective randomizsd controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer","volume":"13","author":"Saad","year":"2017","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3923\/ijcr.2016.69.81","article-title":"Targeting bone marrow to potentiate the anti-tumour effect of tyrosine kinase inhibitor in preclinical rat model of Human glioblastoma","volume":"12","author":"Shaaban","year":"2016","journal-title":"Int. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102886","article-title":"Mechanisms of resistance to mTOR inhibitors","volume":"147","author":"Formisano","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0007","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ijrobp.2023.08.044","article-title":"A phase 2 study of In situ oncolytic virus therapy and stereotactic body radiation therapy followed by Pembrolizumab in metastatic non-small cell lung cancer","volume":"118","author":"Guan","year":"2024","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"10.1016\/j.ctarc.2025.100971_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1473288","article-title":"Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry","volume":"15","author":"Dong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/imt-2023-0124","article-title":"Oncolytic viruses in lung cancer treatment: a review article","volume":"16","author":"Sakhi","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctarc.2025.100971_bib0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40164-024-00570-y","article-title":"CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications","volume":"13","author":"Feng","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0011","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2025.100971_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082352","article-title":"Local delivery of immunomodulatory antibodies for gastrointestinal tumors","volume":"15","author":"Silva-Pilipich","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2025.100971_bib0013","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0014","series-title":"Encyclopedia of Infection and Immunity","first-page":"429","article-title":"Response to viruses","author":"Herbert","year":"2022"},{"key":"10.1016\/j.ctarc.2025.100971_bib0015","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2025.100971_bib0016","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/2326-6066.CIR-22-0927","article-title":"Combination ifn\u03b2 and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunity","volume":"11","author":"Zheng","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112926","article-title":"Ad-apoptin inhibits glycolysis, migration and invasion in lung cancer cells targeting AMPK\/mTOR signaling pathway","volume":"409","author":"Song","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0018","article-title":"Combination therapy with oncolytic viruses for lung cancer treatment","volume":"15","author":"Sun","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0019","doi-asserted-by":"crossref","first-page":"100","DOI":"10.25259\/IJMIO_26_2020","article-title":"Driver mutations in oncogenesis","volume":"6","author":"Morjaria","year":"2021","journal-title":"Int. J. Mol. Immuno. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells13050436","article-title":"Cutting-edge therapies for lung cancer","volume":"13","author":"La\u2019ah","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2025.100971_bib0021","doi-asserted-by":"crossref","first-page":"e1398","DOI":"10.1002\/mgg3.1398","article-title":"Genetic profile of non-small cell lung cancer (NSCLC): a hospital-based survey in Jinhua","volume":"8","author":"Chen","year":"2020","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.ctarc.2025.100971_bib0022","article-title":"Clinical relevance of KRAS in human cancers","author":"Janc\u00edk","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"issue":"Suppl 5","key":"10.1016\/j.ctarc.2025.100971_bib0023","first-page":"S479","article-title":"Molecular biology of lung cancer","volume":"5","author":"Cooper","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ctarc.2025.100971_bib0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0026","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0027","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","article-title":"Oncolytic group B Adenovirus enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators","volume":"4","author":"Dyer","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ctarc.2025.100971_bib0028","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00262-003-0474-8","article-title":"Apoptosis pathways in cancer and cancer therapy","volume":"53","author":"Debatin","year":"2004","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0029","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","article-title":"Activation of apoptosis signalling pathways by reactive oxygen species","volume":"1863","author":"Redza-Dutordoir","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ctarc.2025.100971_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","article-title":"Calreticulin and cancer","volume":"31","author":"Fucikova","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0031","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.lungcan.2021.03.018","article-title":"Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer","volume":"155","author":"Furukawa","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107264","article-title":"Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors","volume":"181","author":"Tsutsumi","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0033","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","article-title":"Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma","volume":"72","author":"Miyamoto","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0034","first-page":"245","article-title":"[Synergistic effect of NF-\u03baB signaling pathway inhibitor and oncolytic measles virus vaccine strain against lung cancer and underlying mechanisms]","volume":"24","author":"Xia","year":"2021","journal-title":"Zhongguo Fei. Ai. Za Zhi."},{"key":"10.1016\/j.ctarc.2025.100971_bib0035","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1128\/JVI.03851-13","article-title":"Mitophagy enhances oncolytic measles virus replication by mitigating DDX58\/RIG-I-like receptor signaling","volume":"88","author":"Xia","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0036","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.trecan.2021.09.003","article-title":"Necroptosis and tumor progression","volume":"8","author":"Yan","year":"2022","journal-title":"Trends. Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e27294","article-title":"Necroptosis-related KLRB1 was a potent tumor suppressor and immunotherapy determinant in breast cancer","volume":"10","author":"Xia","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ctarc.2025.100971_bib0038","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","article-title":"Pyroptosis: mechanisms and diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0039","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.7150\/thno.71086","article-title":"Pyroptosis in inflammatory diseases and cancer","volume":"12","author":"Rao","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ctarc.2025.100971_bib0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0042","first-page":"1514","article-title":"Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells","volume":"8","author":"Ye","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0043","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.18632\/oncotarget.2219","article-title":"Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells","volume":"5","author":"Meng","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2025.100971_bib0044","article-title":"Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy","volume":"13","author":"Palanivelu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/gt.2015.90","article-title":"The targeted inhibitory effects of human amniotic fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small cell lung carcinoma growth","volume":"23","author":"Li","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0129","unstructured":"American Cancer Society., Non-small cell lung cancer stages, (n.d.). https:\/\/www.cancer.org\/cancer\/lung-cancer\/detection-diagnosis-staging\/staging-nsclc.html (accessed June 10, 2024)."},{"key":"10.1016\/j.ctarc.2025.100971_bib0066","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s13402-022-00694-5","article-title":"Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor","volume":"45","author":"Gu","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0127","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.ymthe.2017.05.006","article-title":"Oncolytic VSV primes differential responses to immuno-oncology therapy","volume":"25","author":"Durham","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0046","doi-asserted-by":"crossref","first-page":"12243","DOI":"10.1128\/JVI.78.22.12243-12251.2004","article-title":"Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death","volume":"78","author":"Abou El Hassan","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0047","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1128\/JVI.00241-06","article-title":"Newcastle Disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death","volume":"80","author":"Elankumaran","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0048","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00705-011-0987-y","article-title":"Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus","volume":"156","author":"Bian","year":"2011","journal-title":"Arch. Virol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0049","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ctarc.2025.100971_bib0050","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0051","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0052","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fimmu.2018.00781","article-title":"Natural killer cell recruitment to the lung during Influenza A virus infection is dependent on CXCR3, CCR5, and virus exposure dose","volume":"9","author":"Carlin","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0053","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/cncr.29856","article-title":"Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non\u2013small cell lung cancer patients with <scp>K<\/scp>RAS-activated tumors","volume":"122","author":"Villalona-Calero","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0054","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/sj.mt.6300179","article-title":"Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release","volume":"15","author":"Marcato","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0055","article-title":"Oncolytic Adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0056","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41467-019-09220-y","article-title":"CryoEM structure of adenovirus type 3 fibre with desmoglein 2 shows an unusual mode of receptor engagement","volume":"10","author":"Vassal-Stermann","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2025.100971_bib0057","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2004.02.016","article-title":"Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors","volume":"322","author":"Short","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.ctarc.2025.100971_bib0058","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/mr.45.4.483-501.1981","article-title":"Structure and function of the reovirus genome","volume":"45","author":"Joklik","year":"1981","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.ctarc.2025.100971_bib0059","doi-asserted-by":"crossref","unstructured":"P. Danthi, G.H. Holm, T. Stehle, T.S. Dermody, Reovirus receptors, cell entry, and proapoptotic signaling, in: 2013: pp. 42\u201371. https:\/\/doi.org\/10.1007\/978-1-4614-7651-1_3.","DOI":"10.1007\/978-1-4614-7651-1_3"},{"key":"10.1016\/j.ctarc.2025.100971_bib0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1476-4598-8-47","article-title":"Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells","volume":"8","author":"Sei","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0061","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/ijc.27772","article-title":"A novel role for junctional adhesion molecule-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody","volume":"132","author":"Goetsch","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0062","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/978-1-4614-7651-1_3","article-title":"Reovirus receptors, cell entry, and proapoptotic signaling","volume":"790","author":"Danthi","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0063","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-09-2408","article-title":"Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic","volume":"70","author":"Thirukkumaran","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0064","first-page":"4665","article-title":"The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis","volume":"34","author":"Kotteas","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0065","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-018-03432-4","article-title":"Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein","volume":"9","author":"Nikolic","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2025.100971_bib0067","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2025.100971_bib0068","article-title":"Oligoadenylate synthetase-like aggravated Newcastle disease virus-induced necroptosis in glioma cells","volume":"15","author":"Yu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0069","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/gt.2011.205","article-title":"Measles virus causes immunogenic cell death in human melanoma","volume":"20","author":"Donnelly","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JTO.0000000000000214","article-title":"Measles vaccine strains for virotherapy of non-small-cell lung carcinoma","volume":"9","author":"Patel","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0071","doi-asserted-by":"crossref","first-page":"11307","DOI":"10.1073\/pnas.93.21.11307","article-title":"The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors","volume":"93","author":"Roizman","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ctarc.2025.100971_bib0072","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-1083-3","article-title":"Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity","volume":"10","author":"Stanziale","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0073","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12865-018-0281-9","article-title":"Oncolytic herpes simplex virus and immunotherapy","volume":"19","author":"Ma","year":"2018","journal-title":"BMC. Immunol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009446","article-title":"The herpesvirus accessory protein \u03b3134.5 facilitates viral replication by disabling mitochondrial translocation of RIG-I","volume":"17","author":"Liu","year":"2021","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.ctarc.2025.100971_bib0075","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor\u2013Encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0076","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jdermsci.2007.12.001","article-title":"Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10","volume":"50","author":"Watanabe","year":"2008","journal-title":"J. Dermatol. Sci."},{"issue":"737\u201363","key":"10.1016\/j.ctarc.2025.100971_bib0077","first-page":"764","article-title":"Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management","volume":"57","author":"Fatahzadeh","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0078","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-444-53488-0.00011-0","article-title":"Herpes simplex virus","volume":"123","author":"Widener","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0079","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1242\/jcs.1987.Supplement_7.6","article-title":"The genome of herpes simplex virus: structure, replication and evolution","volume":"7","author":"McGeoch","year":"1987","journal-title":"J. Cell Sci. Suppl."},{"key":"10.1016\/j.ctarc.2025.100971_bib0080","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0081","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0082","doi-asserted-by":"crossref","unstructured":"Ohnesorge Paul V., Efficacy of oncolytic Herpes simplex virus T-VEC combined with BET inhibitors as an innovative therapy approach for NUT carcinoma, (2022). 10.3390\/cancers14112761.","DOI":"10.3390\/cancers14112761"},{"key":"10.1016\/j.ctarc.2025.100971_bib0083","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008025","article-title":"Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?","volume":"12","author":"Wang","year":"2024","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0084","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001701","article-title":"Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany","volume":"9","author":"Ressler","year":"2021","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","article-title":"Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase ib trial","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0086","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004307","article-title":"OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase ib study","volume":"10","author":"Cui","year":"2022","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0087","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2025.100971_bib0088","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.omto.2021.05.004","article-title":"Oncolytic herpes virus G47\u0394 works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation","volume":"22","author":"Sugawara","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ctarc.2025.100971_bib0089","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.omto.2022.07.006","article-title":"Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47\u0394 combination therapy against glioblastoma","volume":"26","author":"Chalise","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ctarc.2025.100971_bib0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized interleukin-12 for cancer immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0091","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0092","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00705-024-05971-2","article-title":"Tracing the journey of poxviruses: insights from history","volume":"169","author":"Siddalingaiah","year":"2024","journal-title":"Arch. Virol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0093","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0065-3527(08)60515-1","article-title":"Vaccinia: virus, vector, vaccine","volume":"34","author":"Piccini","year":"1988","journal-title":"Adv. Virus. Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0094","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0165-2478(98)00125-4","article-title":"Vaccinia virus immune evasion","volume":"65","author":"Smith","year":"1999","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ctarc.2025.100971_bib0095","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1172\/JCI24624","article-title":"Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma","volume":"115","author":"Kaufman","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ctarc.2025.100971_bib0096","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0097","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100971_bib0098","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12935-024-03238-z","article-title":"PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma","volume":"24","author":"Park","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ctarc.2025.100971_bib0099","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000294","article-title":"Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer","volume":"8","author":"Sun","year":"2020","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0100","article-title":"A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16051021","article-title":"Intratumoral delivery of interleukin 9 via oncolytic Vaccinia virus elicits potent antitumor effects in tumor models","volume":"16","author":"Ye","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2025.100971_bib0102","first-page":"646","article-title":"Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review","volume":"20","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ctarc.2025.100971_bib0103","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020240","article-title":"Oncolytic vaccinia virus in lung cancer vaccines","volume":"10","author":"Truong","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ctarc.2025.100971_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101563","article-title":"Lung cancer and oncolytic virotherapy\u2013enemy\u2019s enemy","volume":"27","author":"Li","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0105","doi-asserted-by":"crossref","first-page":"700","DOI":"10.7150\/jca.104066","article-title":"A novel oncolytic virus formulation based on mesenchymal stem cell-derived vesicles for tumor therapy","volume":"16","author":"Zeng","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0106","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0107","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72834-6","article-title":"Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients","volume":"10","author":"Zocco","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2025.100971_bib0109","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.tips.2021.09.001","article-title":"Functional intersections between extracellular vesicles and oncolytic therapies","volume":"42","author":"Clark","year":"2021","journal-title":"Trends. Pharmacol. Sci."},{"key":"10.1016\/j.ctarc.2025.100971_bib0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1039\/D4BM01305K","article-title":"Bioorthogonal oncolytic-virus nanovesicles combined bio-immunotherapy with CAR-T cells for solid tumors","volume":"13","author":"Huang","year":"2025","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ctarc.2025.100971_bib0111","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/jnci\/djh299","article-title":"Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents","volume":"96","author":"Studeny","year":"2004","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2025.100971_bib0112","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7150\/thno.90187","article-title":"Tumor-tropic trojan horses: using mesenchymal stem cells as cellular nanotheranostics","volume":"14","author":"Rosu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ctarc.2025.100971_bib0113","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100782","article-title":"Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing interferon-\u03b2 in preclinical models of non-small cell lung cancer","volume":"13","author":"Patel","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0114","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.2147\/IJN.S455213","article-title":"Nanoparticle-mediated synergistic chemoimmunotherapy for cancer treatment","volume":"19","author":"Lang","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"2024","key":"10.1016\/j.ctarc.2025.100971_bib0115","first-page":"5","article-title":"Nanotechnology-based delivery systems to overcome drug resistance in cancer","volume":"4","author":"Patel","year":"2021","journal-title":"Med. Rev."},{"key":"10.1016\/j.ctarc.2025.100971_bib0116","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jconrel.2022.10.004","article-title":"Nanomedicine for advanced cancer immunotherapy","volume":"351","author":"Diep","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.ctarc.2025.100971_bib0117","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/IJN.S388349","article-title":"How advanced are cancer immuno-nanotherapeutics? A comprehensive review of the literature","volume":"18","author":"Yadav","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ctarc.2025.100971_bib0118","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s11033-021-06876-y","article-title":"Nanotechnology-based products for cancer immunotherapy","volume":"49","author":"Shams","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ctarc.2025.100971_bib0119","first-page":"830","article-title":"Progress in oncolytic viruses modified with nanomaterials for intravenous application","volume":"20","author":"Chen","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ctarc.2025.100971_bib0120","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/acs.biomac.5b00108","article-title":"Protein corona of nanoparticles: distinct proteins regulate the cellular uptake","volume":"16","author":"Ritz","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ctarc.2025.100971_bib0121","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbrc.2020.03.135","article-title":"Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro","volume":"526","author":"Roy","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ctarc.2025.100971_bib0122","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2016-0068","article-title":"Intranasal delivery of nanoparticle-based vaccines","volume":"8","author":"Marasini","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ctarc.2025.100971_bib0123","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41417-023-00717-9","article-title":"A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0124","article-title":"The combination therapy of oncolytic virotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.100971_bib0125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/1535-7163.MCT-15-0695","article-title":"Strategic Combinations: the future of oncolytic virotherapy with reovirus","volume":"15","author":"Zhao","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2025.100971_bib0126","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.lungcan.2018.03.005","article-title":"Canadian Cancer Trials Group (CCTG) IND211: a randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy","volume":"120","author":"Bradbury","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.100971_bib0128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005007","article-title":"Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors","volume":"11","author":"Rudin","year":"2023","journal-title":"J. ImmunOther Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:17:15Z","timestamp":1756934235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":129,"alternative-id":["S2468294225001078"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100971","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy gone viral: Exploring the use of oncolytic viruses in non-small cell lung cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100971"}}